biostudies-literatureYang XBeijing Youth Program for Outstanding TalentsBeijing Medical Award Foundation Youth Committee of Lung Cancer Crowd-funding ProjectBeijing Hospitals Authority Youth ProgrammeBeijing Municipal Administration of Hospitals Incubating Program1107https://www.ebi.ac.uk/biostudies/studies/S-EPMC8520304biostudies-literatureUnknown21(1)<h4>Background</h4>EGFR and ALK alternations often contribute to human malignancies, including lung cancer. EGFR and ALK mutations are usually sensitive to EGFR-tyrosine kinase inhibitors (TKIs) and ALK-TKIs. Although generally mutually exclusive, these mutations do co-exist in rare cases. This study investigated the frequencies, clinical characteristics, therapeutic efficacies, and genetic profiles of lung cancer patients with EGFR and ALK co-mutations.<h4>Methods</h4>Patients with concurrent EGFR and ALK mutations were included in this study, which analyzed mutation profiles and treatment histories. SPSS20.0 were used for survival analysis.<h4>Results</h4>Among 271 ALK-positive (ALK-pos) and 2975 EGFR-positive (EGFR-pos) patients in our database, nine (2.6% of ALK-pos and 0.2% of EGFR-poBMC cancerGenetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations.PMC8520304PX2019038202001001QML201911122018000021469G262PX2020044Yang XZhuo MXia XZhang MZhong JYu ZChen RZhao JfalseGenetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations.<h4>Background</h4>EGFR and ALK alternations often contribute to human malignancies, including lung cancer. EGFR and ALK mutations are usually sensitive to EGFR-tyrosine kinase inhibitors (TKIs) and ALK-TKIs. Although generally mutually exclusive, these mutations do co-exist in rare cases. This study investigated the frequencies, clinical characteristics, therapeutic efficacies, and genetic profiles of lung cancer patients with EGFR and ALK co-mutations.<h4>Methods</h4>Patients with concurrent EGFR and ALK mutations were included in this study, which analyzed mutation profiles and treatment histories. SPSS20.0 were used for survival analysis.<h4>Results</h4>Among 271 ALK-positive (ALK-pos) and 2975 EGFR-positive (EGFR-pos) patients in our database, nine (2.6% of ALK-pos and 0.2% of EGFR-po2021-01-01T00:00:00Z2021 Oct2025-04-22T11:27:11.662Z2025-04-05T23:58:42.005ZS-EPMC85203043465439010.1186/s12885-021-08824-2